,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1471,2,1,,50112780,72474,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
1,1490,2,1,,50112780,72474,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
2,1688,1,1,,50112780,72474,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
3,1766,1,1,,50112780,72474,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
4,1766,1,1,,50112780,72474,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
5,1768,1,1,,50112780,72474,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
6,1768,1,1,,50112780,72474,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
7,2528,1,2,,50112780,72474,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
8,2546,1,1,,50112780,72474,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
9,2551,1,1,,50112780,72474,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
10,2662,2,1,,50112780,72474,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
11,51930,6,6,,103179577,72474,Unspecified,7531135.0,3757.0,104.0,IC50,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,Confirmatory,12190308.0,
12,54107,5,1,,103179577,72474,Unspecified,,,,,Minimum inhibitory concentration required to inhibit DNA gyrase supercoiling.,Other,2002456.0,
13,63899,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity against gram negative organism, Escherichia cloacae (MA2646)",Other,2002456.0,
14,64254,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, E. coli(vogel)",Other,2002456.0,
15,94123,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, K. pneumoniae (MGH-2)",Other,2002456.0,
16,117652,4,3,,103179577,72474,Unspecified,,,,,In vivo oral protective dose was determined in female charles river CD-1 mice infected with Escherichia coli (vogel),Other,2002456.0,
17,117653,3,3,,103179577,72474,Unspecified,,,,,In vivo oral protective dose was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae,Other,2002456.0,
18,117664,3,3,,103179577,72474,Unspecified,,,,,In vivo subcutaneous protective dose was determined in female charles river CD-1 mice infected with Escherichia coli (vogel),Other,2002456.0,
19,117665,3,3,,103179577,72474,Unspecified,,,,,In vivo subcutaneous protective dose was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae,Other,2002456.0,
20,150908,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa (UI-18)",Other,2002456.0,
21,151373,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Providencia rettgeri. (M1771)",Other,2002456.0,
22,161281,10,5,,103179577,72474,Unspecified,7531135.0,3757.0,50.1187,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
23,161284,12,2,,103179577,72474,Unspecified,7531135.0,3757.0,50.0,IC50,Inhibitory activity against Potassium channel HERG,Confirmatory,12747773.0,
24,198020,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus faecalis (MGH-2)",Other,2002456.0,
25,198174,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae (SV-1)",Other,2002456.0,
26,198316,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes (C203)",Other,2002456.0,
27,200230,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (H228)",Other,2002456.0,
28,200231,6,2,,103179577,72474,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (UC76)",Other,2002456.0,
29,226390,8,1,,103179577,72474,Active,,,,,Bacterial minimum inhibitory concentration,Other,12747773.0,
30,230838,3,3,,103179577,72474,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-negative bacteria,Other,2002456.0,
31,230840,3,3,,103179577,72474,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-positive bacteria,Other,2002456.0,
32,243151,7,2,,103179577,72474,Unspecified,,,50.1187,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
33,243188,6,6,,103179577,72474,Unspecified,7531135.0,3757.0,77.6247,IC50,Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state,Confirmatory,15745831.0,
34,276169,11,2,,103179577,72474,Unspecified,7531135.0,3757.0,50.0,IC50,Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay,Confirmatory,16931010.0,
35,408340,8,5,,103179577,72474,Unspecified,7531135.0,3757.0,50.1187,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
36,420668,8,5,,103179577,72474,Unspecified,7531135.0,3757.0,77.6247,IC50,Inhibition of human ERG in MCF7 cells,Confirmatory,19110341.0,
37,420669,3,4,,103179577,72474,Unspecified,,,,,"Lipophilicity, log D at pH 7.0",Other,19110341.0,
38,430965,7,2,,103179577,72474,Unspecified,,,,,Antibacterial activity against Escherichia coli 1596 containing parC K84 mutant assessed as decrease in MIC by Etest relative to MIC for Escherichia coli 1608 containing gyrA mutant,Other,17682104.0,
39,442254,8,3,,103179577,72474,Unspecified,,,10.0,IC50,Antimalarial activity against Plasmodium falciparum 3D7,Confirmatory,19908867.0,
40,442255,8,3,,103179577,72474,Unspecified,,,10.0,IC50,Antimalarial activity against Plasmodium falciparum NF54,Confirmatory,19908867.0,
41,492961,1,1,,50112780,72474,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
42,497756,2,4,,103179577,72474,Unspecified,,,,,"Distribution coefficient, log D of the compound",Other,19822706.0,
43,497757,5,1,,103179577,72474,Unspecified,,,,,Apparent permeability across apical to basolateral side in human Calu3 cells,Other,19822706.0,
44,497758,5,1,,103179577,72474,Unspecified,,,,,Apparent permeability across basolateral to apical side in human Calu3 cells,Other,19822706.0,
45,497759,2,3,,103179577,72474,Unspecified,,,,,Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells,Other,19822706.0,
46,497760,5,1,,103179577,72474,Unspecified,,,,,Apparent permeability across apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor,Other,19822706.0,
47,497761,5,1,,103179577,72474,Unspecified,,,,,Apparent permeability across basolateral to apical side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor,Other,19822706.0,
48,497762,2,3,,103179577,72474,Unspecified,,,,,Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor,Other,19822706.0,
49,498780,5,2,,103179577,72474,Unspecified,,,,,Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method,Other,19805559.0,
50,498781,5,2,,103179577,72474,Unspecified,,,,,Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method,Other,19805559.0,
51,498782,5,2,,103179577,72474,Unspecified,,,,,Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene by agar dilution method,Other,19805559.0,
52,498785,2,3,,103179577,72474,Unspecified,,,,,Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay,Other,19805559.0,
53,498786,2,3,,103179577,72474,Unspecified,,,,,Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay,Other,19805559.0,
54,498787,2,3,,103179577,72474,Unspecified,,,,,Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene at 10 ug by disk diffusion assay,Other,19805559.0,
55,504327,1,1,,50112780,72474,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
56,504332,1,1,,50112780,72474,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
57,504749,1,3,,50112780,72474,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
58,504749,1,3,1.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
59,504749,1,3,2.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
60,504749,1,3,3.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
61,504749,1,3,4.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
62,504749,1,3,5.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
63,504749,1,3,6.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
64,504749,1,3,7.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
65,504749,1,3,8.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
66,504749,1,3,9.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
67,504749,1,3,10.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
68,504749,1,3,11.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
69,504749,1,3,12.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
70,504749,1,3,13.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
71,504749,1,3,14.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
72,504749,1,3,15.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
73,504749,1,3,16.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
74,504749,1,3,17.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
75,504749,1,3,18.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
76,504749,1,3,19.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
77,504749,1,3,20.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
78,504749,1,3,21.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
79,504749,1,3,22.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
80,504749,1,3,23.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
81,504749,1,3,24.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
82,504749,1,3,25.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
83,504749,1,3,26.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
84,504749,1,3,27.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
85,504749,1,3,28.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
86,504749,1,3,29.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
87,504749,1,3,30.0,50112780,72474,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
88,504749,1,3,31.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
89,504749,1,3,32.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
90,504749,1,3,33.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
91,504749,1,3,34.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
92,504749,1,3,35.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
93,504749,1,3,36.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
94,504749,1,3,37.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
95,504749,1,3,38.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
96,504749,1,3,39.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
97,504749,1,3,40.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
98,504749,1,3,41.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
99,504749,1,3,42.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
100,504749,1,3,43.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
101,504749,1,3,44.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
102,504749,1,3,45.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
103,504749,1,3,46.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
104,504749,1,3,47.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
105,504749,1,3,48.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
106,504749,1,3,49.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
107,504749,1,3,50.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
108,504749,1,3,51.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
109,504749,1,3,52.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
110,504749,1,3,53.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
111,504749,1,3,54.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
112,504749,1,3,55.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
113,504749,1,3,56.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
114,504749,1,3,57.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
115,504749,1,3,58.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
116,504749,1,3,59.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
117,504749,1,3,60.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
118,504749,1,3,61.0,50112780,72474,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
119,504832,1,1,,50112780,72474,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
120,504834,1,1,,50112780,72474,Active,,,6.7456,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
121,504847,1,1,,50112780,72474,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
122,504848,1,1,,50112780,72474,Inconclusive,,,15.8489,Potency,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
123,504850,1,1,,50112780,72474,Inconclusive,,,7.0795,Potency,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
124,504865,1,1,,50112780,72474,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
125,576612,7,5,,103179577,72474,Unspecified,7531135.0,3757.0,50.1187,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
126,588209,2,3,,103179577,72474,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
127,588210,2,4,,103179577,72474,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
128,588579,1,1,,50112780,72474,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
129,602332,1,1,,50112780,72474,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
130,624030,1,2,,50112780,72474,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
131,624031,1,2,,50112780,72474,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
132,624032,1,2,,50112780,72474,Inactive,8393992.0,24660.0,0.3613,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
133,624044,1,2,,50112780,72474,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
134,624170,1,1,,50112780,72474,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
135,624172,1,1,,50112780,72474,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
136,624173,1,3,,50112780,72474,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
137,624206,1,1,,50112780,72474,Inactive,,,,Potency,Quantitative high throughput screen to test cell viability of anti-malarial compounds targeting the delayed death phenotype.,Confirmatory,,
138,624296,1,1,,50112780,72474,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
139,624297,1,1,,50112780,72474,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
140,624328,1,1,,50112780,72474,Inconclusive,,,7.0795,Potency,Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid: Hit Validation at 48 hr,Confirmatory,,
141,624329,1,1,,50112780,72474,Active,,,5.98,Potency,Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid: Hit Validation with 3D7 at 48 hr using Flow Cytometry,Confirmatory,,
142,624332,1,1,,50112780,72474,Inconclusive,,,15.8489,Potency,Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid: Hit Validation at 96 hr,Confirmatory,,
143,624335,1,1,,50112780,72474,Active,,,0.6509999999999999,Potency,Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid: Hit Validation with 3D7 at 96 hr using Flow Cytometry,Confirmatory,,
144,624336,1,1,,50112780,72474,Active,,,4.14,Potency,Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid: Hit Validation with Dd2 at 48 hr using Flow Cytometry,Confirmatory,,
145,624337,1,1,,50112780,72474,Active,,,0.479,Potency,Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid: Hit Validation with Dd2 at 96hr using Flow Cytometry,Confirmatory,,
146,625144,5,5,,103179577,72474,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
147,625145,4,7,,103179577,72474,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
148,625146,5,5,,103179577,72474,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
149,625147,4,7,,103179577,72474,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
150,625148,4,7,,103179577,72474,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
151,625149,4,7,,103179577,72474,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
152,625150,5,5,,103179577,72474,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
153,625151,4,7,,103179577,72474,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
154,625152,4,7,,103179577,72474,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
155,625153,4,7,,103179577,72474,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
156,625154,4,7,,103179577,72474,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
157,625155,4,7,,103179577,72474,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
158,625156,1,9,,103179577,72474,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
159,625157,6,2,,103179577,72474,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
160,625158,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
161,625159,5,5,,103179577,72474,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
162,625160,1,9,,103179577,72474,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
163,625161,4,7,,103179577,72474,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
164,625162,4,7,,103179577,72474,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
165,625163,4,7,,103179577,72474,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
166,625164,1,6,,103179577,72474,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
167,625165,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
168,625166,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
169,625167,5,5,,103179577,72474,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
170,625168,4,7,,103179577,72474,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
171,625169,1,6,,103179577,72474,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
172,625170,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
173,625171,4,7,,103179577,72474,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
174,625172,4,7,,103179577,72474,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
175,625173,5,5,,103179577,72474,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
176,625174,5,5,,103179577,72474,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
177,625175,5,5,,103179577,72474,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
178,625176,1,9,,103179577,72474,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
179,625177,5,5,,103179577,72474,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
180,625178,5,5,,103179577,72474,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
181,625179,1,9,,103179577,72474,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
182,625180,5,5,,103179577,72474,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
183,625181,5,5,,103179577,72474,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
184,625182,5,5,,103179577,72474,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
185,625183,5,5,,103179577,72474,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
186,625184,5,5,,103179577,72474,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
187,625185,5,5,,103179577,72474,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
188,625186,5,5,,103179577,72474,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
189,625187,5,5,,103179577,72474,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
190,625188,1,9,,103179577,72474,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
191,625189,1,7,,103179577,72474,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
192,625190,4,5,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
193,625191,4,7,,103179577,72474,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
194,625192,4,7,,103179577,72474,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
195,625193,5,5,,103179577,72474,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
196,625194,4,7,,103179577,72474,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
197,625195,4,7,,103179577,72474,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
198,625196,5,6,,103179577,72474,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
199,625197,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
200,625198,4,7,,103179577,72474,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
201,625199,4,7,,103179577,72474,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
202,625200,4,7,,103179577,72474,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
203,625201,4,7,,103179577,72474,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
204,625202,4,7,,103179577,72474,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
205,625203,4,7,,103179577,72474,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
206,625204,4,7,,103179577,72474,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
207,625205,4,7,,103179577,72474,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
208,625206,4,7,,103179577,72474,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
209,625207,4,7,,103179577,72474,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
210,625208,5,5,,103179577,72474,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
211,625209,4,7,,103179577,72474,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
212,625210,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
213,625211,1,6,,103179577,72474,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
214,625212,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
215,625213,4,7,,103179577,72474,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
216,625214,1,9,,103179577,72474,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
217,625215,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
218,625216,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
219,625217,4,7,,103179577,72474,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
220,625218,4,7,,103179577,72474,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
221,625219,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
222,625220,4,7,,103179577,72474,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
223,625221,4,7,,103179577,72474,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
224,625222,4,7,,103179577,72474,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
225,625223,4,7,,103179577,72474,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
226,625224,3,4,,103179577,72474,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
227,625225,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
228,625226,4,7,,103179577,72474,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
229,625227,4,7,,103179577,72474,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
230,625228,4,7,,103179577,72474,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
231,625229,5,5,,103179577,72474,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
232,625230,1,6,,103179577,72474,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
233,625231,4,7,,103179577,72474,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
234,625232,1,9,,103179577,72474,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
235,625233,4,7,,103179577,72474,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
236,625234,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
237,625235,4,7,,103179577,72474,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
238,625236,5,5,,103179577,72474,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
239,625237,4,7,,103179577,72474,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
240,625238,4,7,,103179577,72474,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
241,625239,4,7,,103179577,72474,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
242,625240,1,9,,103179577,72474,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
243,625241,4,7,,103179577,72474,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
244,625242,4,7,,103179577,72474,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
245,625243,5,5,,103179577,72474,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
246,625244,5,5,,103179577,72474,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
247,625245,5,5,,103179577,72474,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
248,625246,1,9,,103179577,72474,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
249,625247,5,5,,103179577,72474,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
250,625248,5,5,,103179577,72474,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
251,625249,5,5,,103179577,72474,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
252,625250,5,5,,103179577,72474,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
253,625251,5,5,,103179577,72474,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
254,625252,4,7,,103179577,72474,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
255,625253,4,7,,103179577,72474,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
256,625254,4,7,,103179577,72474,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
257,625255,4,7,,103179577,72474,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
258,625256,4,7,,103179577,72474,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
259,625257,4,7,,103179577,72474,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
260,625258,4,7,,103179577,72474,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
261,625259,4,7,,103179577,72474,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
262,625260,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
263,625261,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
264,625262,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
265,625263,4,7,,103179577,72474,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
266,625264,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
267,625265,1,6,,103179577,72474,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
268,625266,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
269,625267,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
270,625268,4,2,,103179577,72474,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
271,625268,4,2,,103179577,72474,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
272,625268,4,2,,103179577,72474,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
273,625268,4,2,,103179577,72474,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
274,625269,4,7,,103179577,72474,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
275,625270,4,7,,103179577,72474,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
276,625271,5,5,,103179577,72474,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
277,625272,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
278,625273,4,6,,103179577,72474,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
279,625274,1,6,,103179577,72474,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
280,625275,3,4,,103179577,72474,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
281,625295,1,3,,103179577,72474,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data,Other,22194678.0,
282,678894,1,8,,103179577,72474,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: uptake in bile canalicular membrane vesicles from EHBR rat,Other,9495864.0,
283,678912,1,8,,103179577,72474,Unspecified,239938877.0,18671.0,,,"TP_TRANSPORTER: increase in Doxorubicin intracellular accumulation (Doxorubicin: 5 uM, GPFX: 500 uM) in P388/ADR cells",Other,11906478.0,
284,678919,1,8,,103179577,72474,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: decrease in intestinal clearance in mdr1a(-/-) mouse,Other,11370709.0,
285,679114,1,8,,103179577,72474,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) of Grepafloxacin at a concentration of 5uM in LLC-GA5-COL150 cells,Other,15032316.0,
286,679486,1,7,,103179577,72474,Unspecified,81886651.0,29509.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,9827570.0,
287,679810,3,6,,103179577,72474,Unspecified,3219824.0,25303.0,1890.0,Ki,TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat,Confirmatory,9495864.0,
288,680109,1,9,,103179577,72474,Unspecified,126927.0,18669.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a/1b(-/-) mouse,Other,10991972.0,
289,680109,1,9,,103179577,72474,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a/1b(-/-) mouse,Other,10991972.0,
290,680124,1,8,,103179577,72474,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Other,11370709.0,
291,680130,2,7,,103179577,72474,Unspecified,238054374.0,5243.0,580.0,Km,TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells,Confirmatory,10992002.0,
292,681459,1,7,,103179577,72474,Unspecified,81911503.0,,,,"TP_TRANSPORTER: increase in biliary excretion by Doxorubicin, Cyclosporin A and Erythromycin in vivo Wistar rat",Other,11906478.0,
293,681512,1,9,,103179577,72474,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: decrease in intracellular accumulation in HL60 and HL60/ADM cells,Other,10991972.0,
294,681991,1,7,,103179577,72474,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, GPFX: 2500 uM) in OCT2-expressing HEK293 cells",Other,12089365.0,
295,682031,1,8,,103179577,72474,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: uptake in bile canalicular membrane vesicles from SD rat,Other,9495864.0,
296,682162,1,7,,103179577,72474,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, GPFX: 2500 uM) in OCT2A-expressing HEK293 cells",Other,12089365.0,
297,682310,1,7,,103179577,72474,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, GPFX: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
298,683718,2,2,,103179577,72474,Active,,,10.0,IC50,Antimalarial activity against liver stages of Plasmodium yoelii yoelii 265 BY infected in mouse after 48 hrs by immunofluorescence assay,Confirmatory,22122518.0,
299,683719,2,3,,103179577,72474,Active,,,10.0,IC50,Antimalarial activity against liver stages of Plasmodium falciparum NF54 in mouse after 72 to 120 hrs by immunofluorescence assay,Confirmatory,22122518.0,
300,755684,2,3,,103179577,72474,Unspecified,7531135.0,3757.0,50.0,IC50,Inhibition of human ERG current by patch clamp assay,Confirmatory,23711922.0,
301,1079931,1,1,,103179577,72474,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
302,1079932,1,1,,103179577,72474,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
303,1079933,1,1,,103179577,72474,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
304,1079934,1,1,,103179577,72474,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
305,1079935,1,1,,103179577,72474,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
306,1079936,1,1,,103179577,72474,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
307,1079937,1,1,,103179577,72474,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
308,1079938,1,1,,103179577,72474,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
309,1079939,1,1,,103179577,72474,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
310,1079940,1,1,,103179577,72474,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
311,1079941,1,1,,103179577,72474,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
312,1079942,1,1,,103179577,72474,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
313,1079943,1,1,,103179577,72474,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
314,1079944,1,1,,103179577,72474,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
315,1079945,1,1,,103179577,72474,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
316,1079946,1,1,,103179577,72474,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
317,1079947,1,1,,103179577,72474,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
318,1079948,1,1,,103179577,72474,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
319,1079949,1,1,,103179577,72474,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
320,1106486,1,2,,103179577,72474,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis,Other,,
321,1125568,1,1,,103179577,72474,Active,,,20.0,IC50,Antimalarial activity against blood stage form of Plasmodium falciparum assessed as incorporation of [3H]hypoxanthine after 72 hrs by liquid scintillation counting,Confirmatory,24650715.0,
322,1224923,1,1,,103179577,72474,Active,,,,,Summary of drugs withdrawn.,Other,,
323,1259310,1,1,,321946252,72474,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
324,1259407,1,1,,363905234,72474,Inactive,,,,,CCRIS mutagenicity studies,Other,,
